Your browser doesn't support javascript.
loading
Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials.
Sonpavde, Guru P; Grivas, Petros; Lin, Yushun; Hennessy, Daniel; Hunt, Jay D.
Affiliation
  • Sonpavde GP; Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA.
  • Grivas P; Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, 1144 Eastlake Ave, E. LG-465, Seattle, WA 98109, USA.
  • Lin Y; PharmStats, Missouri City, TX 77459, USA.
  • Hennessy D; EMD Serono, Inc, Rockland, MA 01821, USA; an affiliate of Merck KGaA, Darmstadt, Germany.
  • Hunt JD; Current affiliation: Constellation Pharmaceuticals, Inc, 215 First St, Suite 200, Cambridge, MA 02142, USA.
Future Oncol ; 17(19): 2545-2558, 2021 Jul.
Article in En | MEDLINE | ID: mdl-33783228
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Drug-Related Side Effects and Adverse Reactions / B7-H1 Antigen / Programmed Cell Death 1 Receptor / Immune Checkpoint Inhibitors / Neoplasms Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Future Oncol Year: 2021 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Drug-Related Side Effects and Adverse Reactions / B7-H1 Antigen / Programmed Cell Death 1 Receptor / Immune Checkpoint Inhibitors / Neoplasms Type of study: Diagnostic_studies / Etiology_studies / Incidence_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Language: En Journal: Future Oncol Year: 2021 Type: Article Affiliation country: United States